The combination of ibrutinib with checkpoint blockade could further improve CD8+ T cell function, highlighting the immuno-therapeutic potential of BTK inhibition via restoring T cell composition and functionality in CLL [18]. The gene discussed is CD8A; the disease is B-cell chronic lymphocytic leukemia.